BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Retlirafusp alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Retlirafusp alfa\, from ClinicalTrials.go
 v estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07550920-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07550920)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for 
 Resectable Stage II-III NSCLC (Phase 2)\nEstimated primary completion: 30 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafu
 sp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07550920
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493382-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Retlirafusp alfa: Phase na readout est. (NCT07493382)
DESCRIPTION:Retlirafusp alfa\, phase na.\nStudy: Retlirafusp Alfa Injection
  Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junc
 tion Adenocarcinoma: A Single-Arm\, Phase II Study of Safety and Efficacy\
 nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07493382
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581574-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Retlirafusp alfa: Phase 1 readout est. (NCT07581574)
DESCRIPTION:Retlirafusp alfa\, phase 1.\nStudy: Neoadjuvant SHR-A1811 and S
 HR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma\
 nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07581574
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618910-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07618910)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Retlirafusp Alfa Plus Chemo
 therapy as Neoadjuvant Therapy for Thoracic ESCC\nEstimated primary comple
 tion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 tlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07618910
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294664-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07294664)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: PDL1/TGFβ
  In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line
  Treatment Of Gastric Cancer\nEstimated primary completion: 15 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07294664
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05503888-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Retlirafusp alfa: Phase 1/2 readout est. (NCT05503888)
DESCRIPTION:Retlirafusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nStu
 dy: Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatm
 ent of Relapsed or Advanced Non-small Cell Lung Cancer\nEstimated primary 
 completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05503888
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814859-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07814859)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Retlirafusp Alfa Combined W
 ith Famitinib\, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of
  Patients With Unresectable Pancreatic Cancer\nEstimated primary completio
 n: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 tlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07814859
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716111-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07716111)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Neoadjuvant SHR-A1811 and S
 HR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ A
 denocarcinoma\nEstimated primary completion: 31 August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07716111
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147088-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07147088)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Cryoablation Combined With 
 SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangioca
 rcinoma.\nEstimated primary completion: 1 September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07147088
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07524374-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07524374)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: SHR-1701 in Combination Wit
 h Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunot
 herapy\nEstimated primary completion: 30 September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07524374
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07102901)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Safety and
  Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or
  Gastro-oesophageal Junction Adenocarcinoma\nEstimated primary completion:
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retli
 rafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07102901
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Stu
 dy of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 E
 xpression Gastric Cancer\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05671822
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893887-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Retlirafusp alfa: Phase na readout est. (NCT06893887)
DESCRIPTION:Retlirafusp alfa\, phase na.\nStudy: Individualized Comprehensi
 ve Treatment for Advanced Hepatocellular Carcinoma\nEstimated primary comp
 letion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06893887
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773363-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07773363)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Retlirafusp Alfa Plus Apati
 nib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer\nEstim
 ated primary completion: 30 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07773363
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478731-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07478731)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Neoadjuvant SHR-1701 Plus C
 hemoradiotherapy for Locally Advanced Rectal Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07478731
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806110-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07806110)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Gemcitabine and Albumin-Bou
 nd Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-
 1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancre
 atic Cancer\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07806110
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817654-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07817654)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Trastuzumab Combined With R
 etlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 
 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-li
 ne Systemic Therapy Failure\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07817
 654
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311408-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07311408)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: SHR-1701 +
  Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy F
 ailure\nEstimated primary completion: 1 January 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07311408
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847710-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07847710)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Perioperative Retlirafusp A
 lfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMO
 X-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrah
 epatic Cholangiocarcinoma: A Multicenter\, Single-Arm\, Exploratory Phase 
 II Trial\nEstimated primary completion: 1 March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07847710
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451795-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07451795)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: SHR-1701 in Combination Wit
 h Stereotactic Body Radiotherapy in mCRPC\nEstimated primary completion: 3
 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlira
 fusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07451795
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503639-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07503639)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Umbrella Trial of Neoadjuva
 nt Therapy for Locally Advanced Colorectal Cancer\nEstimated primary compl
 etion: April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 tlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07503639
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663071-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280527
DTEND;VALUE=DATE:20280528
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07663071)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Short-course Radiotherapy C
 ombined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therap
 y for Locally Advanced Rectal Cancer: A Prospective\, Single-arm\, Phase I
 I Clinical Study\nEstimated primary completion: 27 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07663071
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682376-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07682376)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Low-Dose Radiotherapy With 
 Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Lo
 cally Advanced Esophageal Squamous Cell Carcinoma\nEstimated primary compl
 etion: 30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 etlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07682376
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464756-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07464756)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: SHR-1701 W
 ith or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Th
 erapy for Gastric Cancer\nEstimated primary completion: 31 May 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07464756
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855757-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Retlirafusp alfa: Phase na readout est. (NCT07855757)
DESCRIPTION:Retlirafusp alfa\, phase na\, Gastric Cancer.\nStudy: Retlirafu
 sp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/G
 EJ Cancer With Malignant Ascites\nEstimated primary completion: 30 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0785
 5757
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619911-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07619911)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage I
 II Non-Small Cell Lung Cancer\nEstimated primary completion: July 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07619911
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749859-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07749859)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: SHR-1701 Plus Apatinib for 
 Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellula
 r Carcinoma\nEstimated primary completion: July 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07749859
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689851-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07689851)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Chemoradio
 therapy and SHR-1701 in Patients With Unresectable Gastric Cancer\nEstimat
 ed primary completion: 30 July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07689851
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752550-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07752550)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Retlirafusp Alfa Combined W
 ith Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer\nEstimat
 ed primary completion: 30 July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07752550
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175220-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07175220)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumo
 r Treatments in Non-small Cell Lung Cancer Subjects\nEstimated primary com
 pletion: October 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07175220
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517653-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07517653)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Neoadjuvant SHR-1701 Plus F
 amitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melan
 oma\nEstimated primary completion: 30 November 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07517653
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567326-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07567326)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Re
 sectable NSCLC\nEstimated primary completion: December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07567326
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874425-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07874425)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Retlirafus
 p Alfa Combined With Zeprumetostat\, Apatinib\, and Chemotherapy as First-
 Line Treatment for Metastatic GC/GEJC\nEstimated primary completion: Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp
 -alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07874425
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355010-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07355010)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: A Randomized\, Open-label\,
  Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1
 701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer\nEsti
 mated primary completion: 30 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07355010
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384234-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07384234)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: SHR-1701 Combined With Chem
 otherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peri
 toneal Metastasis\nEstimated primary completion: 30 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07384234
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610629-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07610629)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Retlirafusp Alfa Combined W
 ith Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Ga
 stroesophageal Junction Cancer\nEstimated primary completion: 31 December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alf
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 610629
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677293-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retlirafusp alfa: Phase 3 readout est. (NCT07677293)
DESCRIPTION:Retlirafusp alfa\, phase 3\, Gastric Cancer.\nStudy: Retlirafus
 p Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD
 -1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric
  Cancer With Liver Metastases\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 77293
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802184-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Retlirafusp alfa: Phase 1/2 readout est. (NCT07802184)
DESCRIPTION:Retlirafusp alfa\, phase 1/2.\nStudy: GnP Combined With SHR-170
 1 and Apatinib as First-Line Treatment for Metastatic PDAC\nEstimated prim
 ary completion: 1 January 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/retlirafusp-alfa#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07802184
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770672-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07770672)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: An Exploratory Clinical Stu
 dy of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally
  Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fi
 broblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluor
 o-D-glucose) Dual Imaging\nEstimated primary completion: 1 March 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07770672
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07924332-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07924332)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Retlirafusp Alfa or Adebrel
 imab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric 
 or Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion:
  30 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retli
 rafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07924332
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797244-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07797244)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: A Single-Arm\, Phase II Stu
 dy of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the F
 irst-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver M
 etastases (CRLM)\nEstimated primary completion: April 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07797244
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802288-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07802288)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Phase II Study of Trastuzum
 ab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perio
 perative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal 
 Junction Adenocarcinoma\nEstimated primary completion: 30 April 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07802288
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845565-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07845565)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: FMT Plus SHR-1701 With Nab-
 Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Met
 astatic Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: Ma
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-a
 lfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07845565
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728019-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07728019)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Efficacy and Safety of Retl
 irafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Cours
 e Radiotherapy in Patients With CRCLM\nEstimated primary completion: 30 Ju
 ne 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-
 alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07728019
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709533-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07709533)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: An Umbrella-designed Prospe
 ctive Multicenter Randomized Open-label Superiority Trial Evaluating Multi
 -biomarker-guided Precision Therapy for First-line Treatment of Advanced E
 sophageal Squamous Cell Carcinoma\nEstimated primary completion: 30 June 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 09533
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769866-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Retlirafusp alfa: Phase na readout est. (NCT07769866)
DESCRIPTION:Retlirafusp alfa\, phase na.\nStudy: Retlirafusp Alfa Combined 
 With Chemoradiotherapy in Unresectable ESCC\nEstimated primary completion:
  30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlir
 afusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07769866
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Establishm
 ent of Precision Targeted Therapy Strategies for Advanced Gastric Cancer B
 ased on Novel Molecular Subtyping\nEstimated primary completion: 1 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alf
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 881017
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815288-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07815288)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: Retlirafusp Alfa Plus Targe
 ted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Met
 astases\nEstimated primary completion: 30 December 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07815288
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904442-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07904442)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Applicatio
 n of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric
  Cancer With Peritoneal Metastasis\nEstimated primary completion: 31 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp
 -alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07904442
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934927-2061@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07934927)
DESCRIPTION:Retlirafusp alfa\, phase 2.\nStudy: A Phase II Study of Nab-Pac
 litaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advan
 ced Mucosal Melanoma\nEstimated primary completion: 31 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07934927
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
